Most uterine cancers have excellent five-year survival rates – up to 95% for localized cancer. Serous uterine cancer is an exception, with five-year survival rates of 35% to 50% for stage 1 or 2 ...
Researchers say that in the course of developing a new model for ovarian cancer, they've developed additional evidence that serous uterine cancer possibly begins in the fallopian tubes, not the uterus ...
Researchers have identified the origin of ovarian cancer that develops in the fallopian tube, which opens doors to discovering new methods for diagnosing the disease and potential therapies. The ...
A new research paper was published in Volume 12 of Oncoscience on October 14, 2025, titled "Bridging clinical insight and laboratory model in high-grade serous ovarian carcinoma (HGSOC) using DNA ...
(a) The tumor shows focal glandular architecture along with solid areas (100×, H&E). (b, c) The solid component exhibits prominent lymphocytic infiltrate with tumor heterogeneity (100×, H&E). (d) The ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Gini F. Fleming, ...
In subjects with <=2 prior lines of therapy (LoT), the ORR was 44%. Based on data that showed higher response rates in subjects with serous EC (also called uterine serous carcinoma) across Arm 1 and ...
Most uterine cancers have excellent five-year survival rates – up to 95% for localized cancer. Serous uterine cancer is an exception, with five-year survival rates of 35% to 50% for stage 1 or 2 ...
Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results